Bahman John Moghadam

Bahman Moghadam practices at DaVita Trc/usc Kidney Center in Los Angeles, California.

Bahman Moghadam's NPI, 1215432190, was assigned on March 24, 2018. Bahman Moghadam graduated from Rajiv Gandhi Medical College in 2015. Bahman Moghadam holds California license A173584.

Bahman Moghadam's primary practice is DaVita Trc/usc Kidney Center, at 2310 Alcazar Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 441-9966.

Bahman Moghadam's primary practice is DaVita Trc/usc Kidney Center in Los Angeles, California. Bahman Moghadam is also affiliated with Los Angeles General Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Bahman Moghadam to 3 more group practices and clinics, 3 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Bahman Moghadam practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Bahman Moghadam's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Bahman Moghadam is board certified in internal medicine by the American Board of Internal Medicine. Bahman Moghadam is licensed in California.

Dmand AI lists chronic kidney disease among the conditions Bahman Moghadam treats.

CMS data shows 951 Medicare services from Bahman Moghadam across 6 procedure codes in 2024, for 306 Medicare patients. Medicare paid $69,248 for them.

CMS counts 306 Medicare patients who saw Bahman Moghadam in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 72% are also on Medicaid. Their average risk score is 5.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Bahman Moghadam's median patient age at 59, with 46% women.

In 2024, Bahman Moghadam wrote 155 Medicare Part D claims for 44 patients. 76% of them were for generic drugs. CMS names the drug for 78 of them, across 5 drugs with 11 or more claims each, at $7,476 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Bahman Moghadam for performance year 2024, reported as part of a group. Bahman Moghadam accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Bahman Moghadam in 2025. Bahman Moghadam's most frequent co-authors are Tachaporn Trisha Sangwattanarat, MD, Neeraj Sharma, MD and Neeraj Sharma, MD.

CMS Open Payments shows 13 general payments to Bahman Moghadam from 11 drug and device companies from 2021 to 2024. Food and beverage make up the largest share, 91% of the total. Sanofi and Genzyme US Companies paid the most, $109.

Bahman Moghadam graduated from Rajiv Gandhi Medical College in 2015.

Bahman Moghadam is in network with 5 carriers, including Aetna, LA Care and CMS Medicare. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.